Personalized therapies for diabetes, while showing promise in international studies, is met with healthy skepticism from ...

At 85, Jack Tierney is among the oldest type 1 diabetics in America. There are over 38 million Americans with diabetes, of which 2 million are type 1. A type 1 diabetic’s body produces no insulin and ...

Three individuals, along with the group accused of supplying the peptides, were fined between $5,000 and $10,000 for their ...

Biocon earns USFDA nod for Liraglutide injection, boosting its diabetes drug portfolio. Explore investment opportunities now!

The company aims to start a pivotal trial this year, file for 510(k) clearance in 2027 and launch the device in 2028.

On March 10, 2026, the team led by Dr. An Chiying at Shenzhen Hengsheng Hospital, affiliated with Shanghai Fosun Health, publicly announced that through an innovative integrative medical approach, ...

Insulet said results from its study of a fully closed-loop automated insulin delivery system for type 2 diabetes shows an improvement over standard injection therapy. Insulet said its system showed 68 ...

Biocon Pharma, a subsidiary of Biocon Ltd, has secured approval from the US FDA for its generic Liraglutide injection (gVictoza), used in treating Type 2 Diabetes Mellitus.

GLP-1 RAs were first approved for youth with type 2 diabetes with liraglutide (Victoza) in 2019, followed by semaglutide (Wegovy) and dulaglutide (Trulicity) in 2022. Prior to these approvals, insulin ...

A recent small study has found that people may be able to maintain their weight loss with fewer GLP-1 injections, but this strategy may not be effective for everyone.

Type 1 diabetes (T1D) is an autoimmune condition in which the body's own immune system attacks insulin-producing cells. As a result, patients with T1D must closely monitor their blood glucose (BG) ...

Wegovy is a Food and Drug Administration-approved weight loss medication for people with obesity or those who are overweight with weight-related health conditions. In recent years, interest in ...